Trials / Completed
CompletedNCT02191930
Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma
Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma - a GHSG-NLG Intergroup Phase II Trial -
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- University of Cologne · Academic / Other
- Sex
- All
- Age
- 60 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to determine 1. Objective response rate (ORR), defined as the proportion of patients having CR, CRr or PR in the centrally reviewed restaging after six cycles of chemotherapy 2. Progression-free survival (PFS) 3 years after registration
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | B-CAP | |
| DRUG | Brentuximab Vedotin |
Timeline
- Start date
- 2015-09-01
- Primary completion
- 2022-03-16
- Completion
- 2022-03-16
- First posted
- 2014-07-16
- Last updated
- 2024-08-23
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02191930. Inclusion in this directory is not an endorsement.